Study of the doubly charmed tetraquark T+cc

Quantum chromodynamics, the theory of the strong force, describes interactions of coloured quarks and gluons and the formation of hadronic matter. Conventional hadronic matter consists of baryons and mesons made of three quarks and quark-antiquark pairs, respectively. Particles with an alternative quark content are known as exotic states. Here a study is reported of an exotic narrow state in the D0D0π+ mass spectrum just below the D*+D0 mass threshold produced in proton-proton collisions collected with the LHCb detector at the Large Hadron Collider. The state is consistent with the ground isoscalar T+cc tetraquark with a quark content of ccu⎯⎯⎯d⎯⎯⎯ and spin-parity quantum numbers JP = 1+. Study of the DD mass spectra disfavours interpretation of the resonance as the isovector state. The decay structure via intermediate off-shell D*+ mesons is consistent with the observed D0π+ mass distribution. To analyse the mass of the resonance and its coupling to the D*D system, a dedicated model is developed under the assumption of an isoscalar axial-vector T+cc state decaying to the D*D channel. Using this model, resonance parameters including the pole position, scattering length, effective range and compositeness are determined to reveal important information about the nature of the T+cc state. In addition, an unexpected dependence of the production rate on track multiplicity is observed

Supplementary Material for: Hedgehog pathway- and PD-1 inhibitors for advanced basal cell carcinoma

Here we report in detail the management of three complex advanced BCC (aBCC) cases treated with nivolumab and pembrolizumab after vismodegib failure. All patients were treated with PD-1 inhibitors before cemiplimab was approved by the FDA and EMA. On all tumors next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed and subsequently patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anti-cancer drugs based on the molecular tumor profile

Quality assessment of positron emission tomography scans: recommendations for future multicentre trials

Background: Standardization protocols and guidelines for positron emission tomography (PET) in multicenter trials are available, despite a large variability in image acquisition and reconstruction parameters exist. In this study, we investigated the compliance of PET scans to the guidelines of the European Association of Nuclear Medicine (EANM). From these results, we provide recommendations for future multicenter studies using PET. Material and methods: Patients included in a multicenter randomized phase II study had repeated PET scans for early response assessment. Relevant acquisition and reconstruction parameters were extracted from the digital imaging and communications in medicine (DICOM) header of the images. The PET image parameters were compared to the guidelines of the EANM for tumor imaging version 1.0 recommended parameters. Results: From the 223 included patients, 167 baseline scans and 118 response scans were available from 15 hospitals. Scans of 19% of the patients had an uptake time that fulfilled the Uniform Protocols for Imaging in Clinical Trials response assessment criteria. The average quality score over all hospitals was 69%. Scans with a non-compliant uptake time had a larger standard deviation of the mean standardized uptake value (SUVmean) of the liver than scans with compliant uptake times. Conclusions: Although a standardization protocol was agreed on, there was a large variability in imaging parameters. For future, multicenter studies including PET imaging a prospective central quality review during patient inclusion is needed to improve compliance with image standardization protocols as defined by EANM

Additional file 3: of Learning to use a body-powered prosthesis: changes in functionality and kinematics

Data Kinematics. (TXT 19 kb

Additional file 1 of Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach

Additional file 1: Fig. S1. Mockup example of a medication overview for patients of one of the treatment schedules (Rd; lenalidomide/dexamethasone and co-medication). The text boxes next to the date display time by day or week; The columns represent medication type, medication dose, medication time and additional instructions. Fig. S2. Medication overview of one of the treatment schedules (KRd; carfilzomib/lenalidomide/dexamethasone and co-medication). The menu to the left is identical to figure 3; the columns to the right are comparable to figure S1. Fig. S3. Medication registration page. The menu to the left is comparable to figure 3. Each line represents one medication with information, for example acetylsalicylzuur translates to acetylsalicylic acid and the bold text to ‘dosing’, ‘aim’, ‘brand types’, ‘time of preference’, ‘side effects’, ‘additional remarks’. Fig. S4. Outpatient visit preparation questionnaire (not showing blank space). The menu to the left is comparable to figure 3 and marks ‘Outpatient clinic preparation’. The text contains an introduction asking patients what complaints or side effects they experience at that give moment and states that a patient can tick as many boxes as apply to that moment. Then every line represents one complaint, for example ‘Braken’ means ‘Vomiting’. Fig. S5. Periodic assessment, one question example. The menu to the left is comparable to figure 3 and marks ‘Periodic check’. The question translates to ‘How would you judge your health during the last week?’ and the answers range from ‘very bad’ to ‘excellent’. Fig. S6. Ad hoc complaint form completed, followed by advice. This displays the healthcare provide account, zooming in on one specific part of a questionnaire that was filled out by a patient. The second yellow alert line states the question ‘Do you experience vomiting for more than 24 hours’, as a follow-up question when the patient has ticked ‘vomiting’ in the list in figure S4. At the most right it states that the patient has answered ‘Nee’ (No). Fig. S7. Healthcare provider alert list, including one active alert. This displays the healthcare provider account, highlighting the ‘Interventielijst’ (List of interventions) that indicates a red alert for a given patient at a given time

Additional file 2: of Learning to use a body-powered prosthesis: changes in functionality and kinematics

Data IoF scores. (TXT 951 bytes